Rajeev Saggar
Direttore Tecnico/Scientifico/R&S presso LIQUIDIA CORPORATION
Patrimonio netto: 3 M $ in data 30/06/2024
Profilo
Rajeev Saggar is currently the Chief Medical Officer at Liquidia Corp.
Prior to this, he was the Vice President of Clinical Development at Theravance Biopharma US, Inc. from 2021 to 2022.
He also served as the Medical Director for Pulmonary Hypertension & Fibrosis at The Banner-University Medical Center.
Dr. Saggar holds a doctorate degree from the University of California, Irvine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
LIQUIDIA CORPORATION
0.28% | 19/04/2024 | 211 672 ( 0.28% ) | 3 M $ | 30/06/2024 |
Posizioni attive di Rajeev Saggar
| Società | Posizione | Inizio |
|---|---|---|
| LIQUIDIA CORPORATION | Direttore Tecnico/Scientifico/R&S | 18/07/2022 |
Precedenti posizioni note di Rajeev Saggar
| Società | Posizione | Fine |
|---|---|---|
Theravance Biopharma US, Inc.
 Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Direttore Tecnico/Scientifico/R&S | 01/07/2022 |
| The Banner-University Medical Center | Corporate Officer/Principal | - |
Formazione di Rajeev Saggar
| University of California, Irvine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| LIQUIDIA CORPORATION | Health Technology |
| Aziende private | 1 |
|---|---|
Theravance Biopharma US, Inc.
Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Commercial Services |
- Borsa valori
- Insiders
- Rajeev Saggar
